News

Zacks.com on MSN6d

CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Novo Nordisk's Moat Is Deeper Than You Think

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Zacks.com on MSN6d

Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...